BMX non-receptor tyrosine kinase (BMX)

BMX non-receptor tyrosine kinase is an intracellular enzyme encoded by the *BMX* gene located on chromosome Xp22.2 and is a member of the Tec family of non-receptor tyrosine kinases[3][5][2]. Structurally, BMX contains domains typical of kinases in this family, including a PH (pleckstrin homology) domain, an SH3 domain, an SH2 domain, and a kinase domain[2][3]. BMX is primarily expressed in endothelial cells, bone marrow/myeloid cells, and several cancer types, where it regulates multiple cellular processes such as proliferation, migration, adhesion, apoptosis, angiogenesis, and cellular differentiation[1][2][3][6]. BMX exerts its effects by modulating key signaling pathways—including STAT3 activation, PI3K/AKT, and ERK—often acting downstream of growth factor receptors, integrins, and cytokine receptors[1][3][6]. It is implicated in various human diseases, most notably cancer, where it can promote tumor cell growth and migration through alternative splicing variants (such as BMXΔN)[1]. BMX has also been linked to inflammation and cardiac hypertrophy, suggesting its role in endothelial–parenchymal cross-talk during disease progression[6]. Several small-molecule inhibitors (notably some BTK inhibitors) target BMX in preclinical and clinical studies, although selective BMX inhibition remains an area of active research[3][5]. Due to its involvement in critical cell signaling cascades, BMX is a promising therapeutic target across oncology, inflammation, and cardiovascular disease, with expression or alternative splicing potentially serving as biomarkers of disease or treatment response[1][6][3].

Other names

Bone marrow tyrosine kinase on chromosome XCytoplasmic tyrosine-protein kinase BMXEtkPSCTK3Tyro8

Inhibition of tyrosine kinase activity, leading to blockade of downstream signaling (e.g., STAT pathway, PI3K pathway) in tumor cells and endothelial cells